|
|
On-Demand Webinar: The Adoption Process of Novel Technologies in Preclinical Safety
This webinar took place on November 5, 2008. An archived version of the webinar is available. Please fill out the form below to receivee access.
The Adoption Process of Novel Technologies in Preclinical Safety: Challenges and Solutions.
Register using the form below.
This complimentary, online session featured an expert panel, including:
- Ernie Bush, Ph.D., Vice President and Scientific Director (formerly F. Hoffman-La Roche), Cambridge Healthtech Associates
- Gary Gintant, Ph.D., Visiting Scientist, Clin. Pharm. and Pharmacometrics, Sr. Grp. Ldr, Dept. Integrative Pharm, Abbott Labs
- Judy Marquis, Ph.D., Group Vice President of Pharmacology and Preclinical Development, Genzyme
- George C. McCormick, Ph.D., D.A.B.T., Vice President, Drug Safety & Disposition, Cephalon, Inc.
Some of the questions the panelists addressed included:
- If it were your money, what would be the first thing you would do to improve pharma R&D productivity?
- What areas in preclinical R&D are most open to evaluating/implementing new technologies or novel platforms? Why?
- What areas in preclinical R&D are most resistant to evaluating/implementing new technologies or novel platforms? Why?
- At which level of management is the decision taken to evaluate and adopt a new technology? (Does that decision maker change depending on the size of the organization? Is there any advantage for a provider to establish a preferred agreement with corporate purchasing?)
- How much does the ‘Not Invented Here’ mentality inhibit new technology assessment/implementation in your organization?
- What can be done to lower the barriers for new technology or novel platform adoption?
|